Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Novartis, ImmunoGen Adds $45 Mil. And Another Licensor For Its Antibody-Drug Conjugate Platform

This article was originally published in The Pink Sheet Daily

Executive Summary

The deal gives Novartis access to develop therapeutics against an unspecified number of targets, while ImmunoGen gets more good news on top of positive Phase II data for its lead candidate.
Advertisement

Related Content

Deals Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?
Antibody-Drug Conjugates: The Next Generation Of Moving Parts
ImmunoGen Wants A Bigger Share Of The Antibody-Drug Conjugate Pie
ImmunoGen Wants A Bigger Share Of The Antibody-Drug Conjugate Pie
Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA
Pfizer Pulls Mylotarg For Safety 10 Years After Accelerated Approval
Pfizer Pulls Mylotarg For Safety 10 Years After Accelerated Approval

Topics

Advertisement
UsernamePublicRestriction

Register

PS071292

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel